GlassScriptPhysician profile
Sarah C Mooney
NPI 1285129320
$1,556.16
in general payments reported to CMS, 2019-2025
17 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.52 · 2022: $177 · 2023: $367 · 2024: $782 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $396.85 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $263.05 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $216.71 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $182.26 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $163.53 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $54.69 | 2024 | |
| Inspire Medical Systems, INC. | $40.37 | 2024 | Inspire |
| Amgen INC. | $31.31 | 2022-2024 | Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $30.48 | 2022 | |
| Exact Sciences Corporation | $27.83 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.78 | 2024 | Xifaxan |
| Shield Therapeutics INC | $24.18 | 2023 | Accrufer |
| Intuitive Surgical, INC. | $20.68 | 2023 | Da Vinci Surgical System |
| Idorsia Pharmaceuticals US INC | $20.31 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $19.77 | 2024 | Vaxelis, Capvaxive |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $19.74 | 2023 | Rebyota |
| Axsome Therapeutics, INC. | $16.62 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Mooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.